Huberman LabDr. Natalie Crawford on Huberman Lab: Why AMH drops early
Tracking ovulation and testing AMH early flags fertility reserve loss; meiosis errors, luteal defects, and inflammation compound age effects on fertility.
CHAPTERS
Dr. Natalie Crawford’s framework: fertility as a window into whole-body health
Huberman introduces Dr. Natalie Crawford and frames fertility as more than pregnancy—it's a marker of hormonal, metabolic, and cellular health. Crawford explains how infertility often correlates with broader health risks, not because it directly causes them, but because it can be an early warning sign of underlying inflammation or insulin resistance.
- •Fertility reflects coordinated hormonal, metabolic, and cellular function
- •Infertility correlates with higher risk of metabolic syndrome, cardiovascular disease, some cancers, and earlier mortality
- •Infertility often signals underlying chronic inflammation/insulin resistance rather than causing disease
- •Why fertility knowledge matters even for people unsure about having children
Perimenopause & menopause: redefining ovarian aging and hormone therapy timing
Crawford explains perimenopause as a long transition where cycle changes and hormone symptoms can begin years before the traditional menopause definition. She and Huberman discuss why waiting for strict cutoffs (e.g., 12 months without a period) can delay helpful care and how hormone therapy is increasingly viewed as beneficial when appropriately timed.
- •Perimenopause can last 5–10 years and still includes pregnancy potential if cycles persist
- •Menopause as “one day” after 12 months without a period; biologically reflects ovarian failure
- •Hormone therapy may be beneficial before the traditional menopause milestone
- •Distinguishing hormone “replacement” vs “augmentation” and symptom-guided care
- •Concerns about historical fear-based messaging (e.g., WHI) and shifting clinical attitudes
Extending ovarian function: inflammation, autoimmune disease, and lifestyle leverage points
The conversation shifts to what might influence ovarian lifespan beyond genetics, emphasizing inflammation and autoimmune associations with earlier ovarian insufficiency. Crawford outlines how managing inflammatory conditions and lifestyle choices could plausibly slow ovarian aging, even if definitive trials are limited.
- •POI/early ovarian failure often linked with inflammation, fibrosis, autoimmune disease
- •Endometriosis/Hashimoto’s and other inflammatory disorders can affect ovarian function
- •Lifestyle patterns that reduce inflammation may support longer ovarian function
- •Avoiding all toxins is impossible—focus on reducing cumulative burden
- •Early identification and treatment of inflammatory drivers may improve outcomes
Plastics, microplastics & endocrine disruption: what’s known and what to do
Crawford addresses concern about plastics and endocrine-disrupting chemicals, emphasizing practical risk reduction rather than perfectionism. She highlights observational links between certain exposures and worse fertility/IVF outcomes while acknowledging confounding factors and the importance of cumulative exposure.
- •Microplastics can accumulate in reproductive tissues including ovaries
- •Endocrine disruptors associated with longer time-to-pregnancy and worse IVF outcomes (observational data)
- •Risk is cumulative; focus on high-frequency exposures (water bottles, food packaging, etc.)
- •Avoid “all-or-nothing” thinking; make scalable improvements
- •Toxins often intersect with diet (e.g., ultra-processed foods/packaging)
Prior pregnancy, secondary infertility, and why earlier testing matters (including sperm)
Crawford reviews data showing prior live birth can improve fecundability (month-to-month pregnancy probability) for a time, but secondary infertility is real and emotionally complex. She strongly argues against the “fail-first” model and emphasizes early evaluation—especially semen testing—to prevent wasted time.
- •Fecundability declines sharply with maternal age; prior live birth offers partial protection until ~37
- •Secondary infertility: common, unexpected, and socially isolating for patients
- •Many couples waste time because semen isn’t tested early; ejaculate ≠ sperm
- •Earlier evaluation can catch blocked tubes, uterine anomalies, anovulation, low reserve, azoospermia
- •Mail-in/CLIA-certified semen analyses can be valid alternatives to clinic testing
Pregnancy loss, termination, and conceiving again: evaluation thresholds and uterine health
Crawford discusses pregnancy loss compassionately, including her personal experience, and explains how loss can still indicate some intact fertility pathways while requiring timely evaluation. She clarifies that abortion/termination doesn’t inherently cause infertility, but any intrauterine procedure can carry scarring risk, especially with infection or heavy bleeding.
- •Pregnancy loss is often due to random embryo genetics; doesn’t imply future infertility
- •After two losses, evaluation is warranted (shift away from the old “three losses” rule)
- •Workup can include labs, semen analysis, sperm fragmentation, uterine/tubal evaluation
- •Termination is not shown to reduce fertility; complications (infection/bleeding) are the key concern
- •Post-procedure lighter periods can signal uterine scarring; saline sonogram can assess
Core reproductive biology: egg number vs egg quality and how the menstrual cycle works
Crawford gives a detailed, practical explanation of ovarian physiology: women are born with their egg supply, eggs leave the ‘vault’ each month, and ovulation depends on FSH/LH and estrogen/progesterone signaling. She distinguishes egg quantity (reserve) from egg quality (genetic normalcy/competency) and explains why age is an imperfect proxy for quality.
- •Egg supply declines from millions in fetal life to hundreds of thousands by menarche
- •Monthly follicular recruitment + FSH/LH dynamics; estrogen triggers LH surge and ovulation
- •Luteal phase progesterone is essential for implantation and cycle regularity
- •Egg quality relates to chromosomal integrity + mitochondrial competency; worsens with time and metabolic health
- •You can still carry pregnancy after ovarian failure with donor eggs/embryos
Tooling for planning: AMH testing, what it means, and why Crawford recommends it broadly
Crawford argues most women who might want children should get an AMH (anti-Müllerian hormone) test to understand ovarian reserve, despite professional guidelines discouraging it absent infertility. She explains what AMH can and cannot tell you, why low AMH prompts investigation for root causes, and how the information changes decision-making.
- •AMH estimates ovarian reserve (egg quantity), not egg quality or immediate fertility
- •Guidelines often discourage AMH screening due to anxiety/limited prediction of natural conception
- •Crawford’s stance: knowledge enables autonomy, earlier planning, and targeted evaluation
- •Low AMH can signal treatable contributors (autoimmune disease, endometriosis, smoking, insulin resistance)
- •AMH can be ordered via doctor, fertility clinic, or direct-to-lab options
Ovulation tracking as a health marker: luteal phase defects and hidden ovulatory problems
Beyond ‘regular periods,’ Crawford emphasizes tracking ovulation to detect subtle dysfunction earlier. She explains how ovulatory disorders often begin with luteal phase shortening, then progress into delayed ovulation and irregular cycles—patterns that may be missed if someone tracks only bleeding dates.
- •Ovulation tracking provides more actionable data than cycle-length tracking alone
- •Short luteal phase (<11 days) can be an early sign of ovulatory dysfunction
- •Progression pattern: short luteal phase → delayed ovulation → irregular cycles/amenorrhea
- •Earlier detection can prompt targeted labs (thyroid, prolactin, AMH, PCOS evaluation)
- •Better timing of intercourse and improved time-to-pregnancy with fertile window targeting
Egg freezing & IVF realities: what it does (and doesn’t) do to ovarian reserve + ethical considerations
Crawford debunks the myth that egg freezing or IVF causes earlier menopause; stimulation simply rescues eggs that would otherwise undergo natural attrition that month. She also discusses embryo vs egg freezing, attrition rates from egg to live birth, embryo disposition concerns, and the policy/insurance landscape.
- •Egg freezing/IVF does not ‘tap into the vault’ or reduce long-term ovarian reserve
- •Stimulation matures the cohort already recruited that month; otherwise most would die naturally
- •Attrition funnel: thaw survival, fertilization, blastocyst formation, genetic normalcy, live birth odds
- •Ethical concerns often center on embryo personhood and disposition; options include egg freezing, limited fertilization, embryo donation
- •Insurance coverage varies by state; even cancer-related fertility preservation is inconsistently covered
Hormonal birth control and return to fertility: pill vs IUD vs Depo-Provera
Crawford explains that large studies don’t show higher long-term infertility rates after contraception, but specific methods can delay optimal conception timelines. She highlights the short half-life of the pill, the endometrial rebuilding period after progesterone IUD removal, and Depo-Provera’s uniquely prolonged ovulation suppression in some people.
- •Population studies: contraception does not increase infertility rates at 12 months post-stop
- •Pill: ovulation should resume quickly; underlying PCOS often masked by pill use
- •Progesterone IUD: may impair endometrial receptivity temporarily; remove ~6 months before trying
- •Depo-Provera: a single shot can suppress ovulation up to ~18 months in some individuals
- •Practical guidance: stop certain methods early to learn cycles/ovulation and avoid timeline surprises
Lifestyle & supplement protocol for “trimester zero”: inflammation, sleep, NSAIDs, and key supplements
Crawford lays out actionable “do, don’t do, and take” principles for improving egg/sperm quality, emphasizing sleep and overall inflammatory load. She warns that anti-inflammatory NSAIDs can prevent follicle rupture around ovulation, discusses melatonin dosing nuance, and outlines commonly used preconception supplements with better evidence.
- •Acute inflammation is required for ovulation/implantation; chronic inflammation is harmful
- •Avoid NSAIDs around ovulation; they can prevent follicle rupture (egg release)
- •Sleep: strong associations with fertility, hormones, sperm counts, IVF outcomes; prioritize circadian consistency
- •Melatonin: low doses (1–3 mg) may help some; avoid high-dose products
- •Common preconception supplements: prenatal (folate), CoQ10, omega-3s, vitamin D; sperm support includes L-carnitine, zinc/selenium
Emerging and debated interventions: red light, GLP-1s for endometriosis, HGH, PRP, and paternal age
The episode closes with a tour of newer or less-settled tools and risk factors. Crawford discusses promising-but-inconclusive areas like red light therapy, GLP-1 agonists for inflammatory infertility/endometriosis (independent of weight loss), add-ons such as HGH in IVF, PRP approaches, and advanced paternal age risks.
- •Red light: early signals of benefit; systemic vs ovary-directed approaches (including intravaginal devices)
- •GLP-1 agonists: potentially anti-inflammatory benefits in suspected endometriosis/unexplained infertility; requires careful dosing and specialist oversight
- •HGH as an IVF add-on: may improve egg maturity/embryo development in select patients despite limited FDA-indicated use
- •PRP: more promising intrauterine PRP for implantation failure than ovarian PRP; ovarian PRP more invasive and less settled
- •Advanced paternal age (>50): small but real increases in de novo mutations and neuropsychiatric risks; optimize male lifestyle and consider sperm banking earlier
Behavioral toxins & everyday endocrine disruptors: cannabis, nicotine, fragrances, receipts, and biotin lab interference
Crawford highlights high-impact exposures that are modifiable and often underestimated. She details strong associations between cannabis and impaired sperm/egg outcomes, addresses nicotine’s harms (especially via smoking data), explains how fragrance/thermal receipts can increase endocrine disruptor exposure, and warns that biotin can distort hormone lab results.
- •Cannabis: major detriment to sperm parameters and miscarriage risk; also reduces eggs retrieved and fertilization rates in women
- •Nicotine/smoking: associated with reduced ovarian reserve and earlier menopause; likely harms fertility even via newer delivery methods
- •Endocrine disruptors: prioritize reducing frequent exposures (fragrances/phthalates, plastics, thermal receipts/BPA)
- •‘Unscented’ ≠ fragrance-free; fragrance-free is the meaningful label
- •Biotin ≥300 mcg/day can interfere with hormone assays (estradiol, progesterone, hCG, TSH, testosterone) leading to false lab reads
